# Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT06914011** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Asan Medical Center** · enrollment: 172 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT06914011
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2031-02-28
- **Final completion:** 2034-05-30
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06914011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06914011, "Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06914011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*